Schedule 13G ownership disclosure

Avalo Therapeutics, Inc.

Common Stock, $0.001 Par Value · CUSIP: 05338F306

Event date: 2025-03-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Ikarian Capital, LLC

    Shares: 1,191,957 · Class: 9.99%

  • Neil Shahrestani

    Shares: 1,191,957 · Class: 9.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-072881
Form type
SCHEDULE 13G/A
Filer
Avalo Therapeutics, Inc.
CIK
CIK 1534120
Filed
May 15, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub